Competitive Landscape in the Pharmaceutical Packaging Equipment Industry: Recent Mergers & Partnerships

The pharmaceutical packaging equipment industry is at a critical inflection point. As demand for advanced, compliant, and scalable packaging machinery intensifies—driven by biologics, serialization requirements, and contract manufacturing—key players are consolidating and forming strategic alliances to strengthen their technological capabilities, geographic reach, and service networks. In this competitive environment, mergers, acquisitions, and partnerships are not just defensive moves; they’re deliberate bets on future growth drivers.

Market Structure and Competitive Forces

The global pharmaceutical packaging equipment market is highly fragmented, with several leading OEMs and machinery vendors actively competing. According to market research, prominent players include IMA Group, Syntegon Technology, Marchesini Group, Uhlmann Group, Körber AG, Bausch + Strobel, Coesia, Vanguard, MULTIVAC, OPTIMA, and ACG Worldwide, among others.

These companies operate across various segments — blister machines, vial filling & sealing, cartoning, labeling, serialization, and inspection systems. As regulatory demands become more stringent and technology adoption accelerates, OEMs are looking beyond organic growth and placing big bets on M&A and partnerships.

Recent M&A Activity: Strategic Consolidation

Gerresheimer Acquires Bormioli Pharma

One of the most notable recent mergers was Gerresheimer’s acquisition of Bormioli Pharma (Blitz LuxCo Sarl, parent of Bormioli Pharma). Through this deal, Gerresheimer expanded its production footprint in Europe, particularly in southern regions, enhancing its capacity to serve pharmaceutical clients with packaging products made of plastic and glass. The acquisition not only strengthens Gerresheimer’s global position but aligns with the demand for integrated packaging solutions from pharma companies operating across regional markets.

IMA Group Acquires Sarong Division

Another strategic move was by I.M.A. Industria Macchine Automatiche S.p.A., which acquired Sarong’s packaging machinery and e‑packaging materials divisions in August 2024. This gives IMA a stronger foothold in specialized pharma packaging, particularly in unit-dose formats and suppositories, and enhances its portfolio for sustainable packaging materials. The deal is a clear signal that OEMs are not just buying machines—they are building full-system capabilities, including materials and specialized equipment, to serve pharma packaging needs more comprehensively.

Partnerships & Strategic Alliances: Innovation + Compliance

M&A isn’t the only story. Strategic partnerships are increasingly common, especially when it comes to combining technical capabilities, regulatory compliance, and distribution networks.

ATS & Paxiom Group

In mid‑2024, ATS Corporation, a Canadian automation company, announced it would acquire Paxiom Group — a provider of packaging machines for regulated industries including pharmaceuticals. While this is technically an acquisition, it’s deeply strategic: ATS gains access to pharma-grade filling, primary packaging, and end-of-line machines, while leveraging Paxiom’s existing customer base in the healthcare space. This deal strengthens ATS’s presence in highly regulated markets and signals its commitment to long-term investment in life sciences.

Amcor and Berry Global Merger

Perhaps the most transformative deal in the broader packaging world, with implications for pharma, is Amcor’s acquisition of Berry Global in an $8.43 billion all-stock deal. Amcor and Berry both have strong positions in healthcare packaging (closures, containers, rigid packaging), and their combined scale and R&D capability will have downstream effects on pharmaceutical packaging equipment demand. Their complementary portfolios and global reach can enable more integrated, end-to-end solutions for pharma companies.

Joint Innovation in Serialization / Track‑and‑Trace

While specific pure-play packaging‑equipment partnerships for serialization are not always publicly disclosed, the broader trend is clear: packaging OEMs are increasingly collaborating with software/data firms, printing‑technology vendors, and quality-inspection companies to deliver integrated track‑and‑trace solutions. According to MarketsandMarkets, major players are investing in R&D and partnerships specifically to develop track‑and‑trace, aggregation, and serial printing capabilities.

Strategic Implications of Consolidation

1. Scale + Geographic Reach

M&A enables equipment manufacturers to scale manufacturing, R&D, and service capabilities more quickly than through organic growth. For example, Gerresheimer’s acquisition of Bormioli Pharma gives it production and sales footprint in new European geographies. For Amcor and Berry, their merger provides a combined global footprint and cross-selling synergies, including in the pharmaceutical sector.

2. Technology & Product Portfolio Expansion

The IMA-Sarong deal illustrates how OEMs are acquiring not just machines but materials and specialty formats. This strengthens their ability to offer complete solutions for pharma customers who are increasingly demanding niche packaging formats (e.g., unit-dose, suppositories) as well as sustainability-oriented materials.

3. Regulatory Alignment

As regulatory requirements (e.g., serialization, clean-room compatibility, data integrity) become stricter, packaging equipment providers must integrate more capabilities into their systems. By acquiring or partnering with specialized firms, OEMs can embed verification, inspection, and data-logging modules directly into their lines. This helps end users (pharmaceutical companies) meet compliance more easily.

4. Service and Aftermarket Strength

Through mergers, OEMs can build broader service networks, reduce downtime, and improve spare-part availability. For pharma customers, this means lower risk, faster maintenance, and better validation support—especially critical for sterile or high-value product lines.

Risks & Challenges

Despite the strategic intent, this M&A activity comes with risks:

• Integration Risk: Merging different organizational cultures, especially when it involves high-precision engineering or life-science compliance systems, can be difficult. OEMs must carefully manage integration of technology platforms, quality systems, and customer support to ensure continuity.
• Regulatory Risk: The regulatory environment is constantly evolving (e.g., serialization requirements, data‑integrity rules). Acquired firms must be brought into compliance quickly or risk nonconformity.
• Capital Intensity: Acquisitions in packaging are capital intensive. For example, acquiring machinery divisions or investing in new production lines requires large upfront investment. Not all companies may realize immediate ROI.
• Customer Risk: Some pharma companies may be cautious about reliance on consolidated suppliers, especially when it comes to critical or sterile packaging operations. They may demand dual-sourcing to reduce dependency risk.

What This Means for Different Stakeholders

For OEMs (Equipment Makers):

• Investments in M&A are not just about scale—they’re about building integrated systems that address specific pharma needs (sterility, serialization, unit-dose, sustainable materials).
• OEMs should also focus on service expansion and global validation support, to support large pharma customers.
• Offering modular, upgradeable platforms post‑acquisition can help reduce buyer friction and make integration smoother.

For Pharmaceutical Companies & CDMOs:

• Consolidation among packaging-equipment OEMs can simplify procurement—fewer vendors, more comprehensive solutions.
• But firms should still evaluate supplier risk, especially around flexibility, geographic support, and future-proofing.
• They may benefit from locking in service agreements and validation packages, especially for sterile or high-value lines.

For Investors / Private Equity:

• Packaging machinery in pharma is a high-technology, high-growth vertical, and M&A deals reflect broader secular trends (automation, serialization, sustainability).
• Firms that back OEMs with strong R&D pipelines or differentiated capabilities (e.g., isolator-compatible, track-and-trace ready machines) may capture disproportionate value.

Outlook: What’s Next in Packaging M&A & Partnerships

• More Tech Acquisitions: Expect further consolidation around software and digital traceability capabilities. OEMs will likely acquire or partner with data-centric firms to embed serialization, blockchain, and IoT into packaging lines.
• Sustainability Push: As pharma companies push for eco-friendly packaging (lightweight materials, recyclable films), OEMs will acquire or partner with material‑science firms, bioplastic developers, and flexible‑packaging specialists.
• Regional Expansion: There is ample room for consolidation in emerging markets (Asia-Pacific, Latin America). Mature OEMs may acquire or partner with regional machine builders or contract packagers to tap into these growth markets.
• Service Optimization: Value will increasingly come not just from machines but from after-sales service — remote diagnostics, validation-as-a-service, predictive maintenance. Partnerships with IT firms, cloud service providers, and specialized service organizations will grow.

For detailed market size, share, competitive landscape and regional analysis, view the full report description of “Global Pharmaceutical Packaging Equipment Market“

Conclusion

The competitive landscape of the pharmaceutical packaging equipment industry is rapidly evolving. Driven by regulatory pressures, demand for automation, and the need for scalable and integrated solutions, key players are consolidating through M&A and forming strategic alliances. Deals such as Gerresheimer’s acquisition of Bormioli Pharma and IMA’s purchase of Sarong’s packaging machinery business reflect a broader shift: packaging OEMs are no longer just selling machines — they are becoming full-system providers.

For pharmaceutical companies, this consolidation offers the potential of streamlined sourcing, advanced technology access, and better after-sales support. But it also raises questions about supplier diversity and dependency. For OEMs, the challenge will be ensuring that they can integrate acquired businesses, deliver validated and compliant systems, and continue to innovate in a highly dynamic market.

Ultimately, the future of the pharma packaging equipment industry hinges not just on the strength of individual companies, but on their ability to align M&A strategies, technological innovation, and customer-centric service models in a fast-changing world.